Eggert’s first task will be to prepare and market Lundbeck’s two new flagship products: nalmefene, to treat alcohol dependence, and the new antidepressant, LUAA21004. Both products are currently in the final stage of development, and are expected to reach patients in 2012 and 2013, respectively.
To build continuity and synergy across drug development phases through to market launch, Andreas Eggert will report to both Stig Løkke Pedersen, executive vice president of commercial operations, and Anders Gersel Pedersen, executive vice president of drug development.
Eggert has broad experience from more than ten years at Pfizer and Wyeth. He was most recently responsible for Pfizer's launch of a new antidepressant.
‘Andreas is the perfect match for us. In addition to his extensive global marketing and launch, just as those which we are currently planning, he also has great professional and personal knowledge of some of our key markets, as he has both worked and lived in the US, Japan and Germany,’ said Stig Løkke Pedersen, Lundbeck's executive vice president of commercial operations.
